drugset / Trial / NCT04686760
Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
In current analysis moderate to severely ill Covid-19 infected patients will be nebulized with nitroglycerin, and they will be compared with the standard nebulization
Timeline
- Start
- 2020-11-15
- Primary completion
- 2021-12-15
- Completion
- 2022-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nitroglycerin | Unknown | 2 mg/ml | Other |